



## Les traitements de demain

Shibeshih Belachew

C.H.U. de Liège


[www.sepmydream.net](http://www.sepmydream.net)

**Journée médicale du 25 juin 2011**


A la date du 24 juin 2011:

735 études cliniques en cours ou clôturées récemment et dont l'analyse est en cours ! <http://clinicaltrials.gov>

### Objectifs des traitements




MSFC=Multiple Sclerosis Functional Composite; SF36-QOL=Short-Form 36 Quality of Life.




MSFC=Multiple Sclerosis Functional Composite; SF36-QOL=Short-Form 36 Quality of Life.

## Choisir un traitement dans la SEP


Une part d'inconnu




## Les options




## Fingolimod et récepteurs à la sphingosine-1-P




## Fingolimod et récepteurs à la sphingosine-1-P






**Fingolimod**  
Mécanisme d'action




冬虫夏草  
*Cordyceps sinensis*


- Agit en superagoniste des récepteurs à la spingosine-1-phosphate
- Induit l'internalisation des récepteurs S1P-R
- Prive les lymphocytes du signal nécessaire à leur sortie du thymus et des ganglions
- Augmente l'entrée des lymphocytes dans les ggl depuis le sang
- Les lymphocytes circulant et les **lymphocytes effecteurs** sont **séquestrés** dans les organes lymphoïdes (ggl, plaques de Peyer)




Brinkmann V et al. J. Biol. Chem. 2002;  
Mandala S et al. Science 2002;  
Brinkmann V et al. Am. J. Transplant. 2004;  
Matloubian M et al. Nature 2004;  
NEJM 2006;355(11):1088




**Fingolimod et récepteurs à la sphingosine-1-P**



冬虫夏草  
*Cordyceps sinensis*






### Etudes cliniques de phase III

**Tysabri**

**Gilenya**

**AFFIRM**

**FREEDOMS**



Polman CH et al. N Engl J Med. 2006;354:899-910; Havrdova E et al. Lancet Neurol. 2009;8:254-260; Munschauer F et al.ECTRIMS; September 2008, Montréal, Canada. Abstract #P474; Hutchinson et al. J Neurol. 2009 Mar;256(3):405-15. Epub 2009 Mar 18. Erratum in: J Neurol. 2009 Jun;256(6):1035-7.

Fingolimod EPAR Gilenya Assessment report EMA/108602/2011


### Etudes cliniques de phase III

**Tysabri**

**Gilenya**



**AFFIRM**

**FREEDOMS**







Polman CH et al. N Engl J Med. 2006;354:899-910; Havrdova E et al. Lancet Neurol. 2009;8:254-260; Munschauer F et al.ECTRIMS; September 2008, Montréal, Canada. Abstract #P474; Hutchinson et al. J Neurol. 2009 Mar;256(3):405-15. Epub 2009 Mar 18. Erratum in: J Neurol. 2009 Jun;256(6):1035-7.

Fingolimod EPAR Gilenya Assessment report EMA/108602/2011




## D'autres pistes ?



## FAMPYRA (4AP-SR)

Walking speed (post-hoc analysis)

Responders: fampridine (36.7%), placebo (8.5%)




29/6/07


## FAMPYRA (4AP-SR)

NEUROLOGY

Dose comparison trial of sustained-release fampridine in multiple sclerosis  
A. D. Coombs, T. R. Brown, J. A. Cohen, L. B. Krupp, R. Schagen, S. E. Schulz, R. Cohen, L. S. Steinman, A. R. Wright and For the Fampridine MSAT2 Study Group  
Neurology 2007; 71: 1114-1121 originally published online July 10, 2007  
DOI: 10.1212/01.wnl.0000262118.00000




29/6/07



## FAMPYRA (4AP-SR)

Walking speed (post-hoc analysis)

Responders: fampridine (36.7%), placebo (8.5%)



29/6/07

## Choisir un traitement dans la SEP Une part d'inconnu



[www.sepmydream.net](http://www.sepmydream.net)